FDA Approves Imcivree for Rare Genetic Obesity Disorders
The FDA has approved Imcivree™ (setmelanotide; Rhythm Pharmaceuticals) for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency.
All articles by Brian Park, PharmD
Risankizumab Superior to Secukinumab in Plaque Psoriasis Trial
AbbVie announced positive topline data from a phase 3 study evaluating the efficacy and safety of risankizumab (Skyrizi) compared with secukinumab (Cosentyx; Novartis) in adult patients with moderate to severe plaque psoriasis.
Bimekizumab Beats Adalimumab in Plaque Psoriasis Trial
UCB announced positive results from the phase 3 BE SURE study of bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis compared with adalimumab.
-
Loading...
-
Loading...
